In patients receiving a stent (BMS or DES) dur- ing PCI for ACS, P2Y12 inhibitor therapy should be given for at least 12 months. Options include (Level of Evidence: B) b. In patients receiving DES for a non-ACS indica- tion, clopidogrel 75 mg daily should be given for at least 12 months if patients are not at high risk of bleeding.208,212,571 (Level of Evidence: B) c. In patients receiving BMS for a non-ACS indica- tion, clopidogrel should be given for a minimum of 1 month and ideally up to 12 months (unless the patient is at increased risk of bleeding; then it should be given for a minimum of 2 weeks).208,572 (Level of Evidence: B) Class IIa 1. After PCI, it is reasonable to use aspirin 81 mg per day in preference to higher maintenance doses.302,573 576 (Level of Evidence: B) 2. If the risk of morbidity from bleeding outweighs the anticipated benefit afforded by a recommended du- ration of P2Y12 inhibitor therapy after stent implan- tation, earlier discontinuation (eg, <12 months) of P2Y12 inhibitor therapy is reasonable. (Level of Evidence: C) Class IIb 1. Continuation of DAPT beyond 12 months may be considered in patients undergoing DES implanta- tion.567,568 (Level of Evidence: C) Class III: HARM 1. Prasugrel should not be administered to patients with a prior history of stroke or transient ischemic attack.567 (Level of Evidence: B) Aspirin reduces the frequency of ischemic complications after PCI. Although the minimum effective aspirin dosage in the setting of PCI has not been established, aspirin 325 mg given at least 2 hours, and preferably 24 hours, before PCI is recommended,302,303 after which aspirin 81 mg daily should be continued indefinitely. Several investigations have explored various loading doses of clopidogrel before or during PCI. 